'TPG Working With JPMorgan Chase Bankers To Explore Potential $5 Billion Sale Of Healthcare Payments Software Firm Lyric, Sources Said' - Reuters Exclusive
Key takeaways
- TPG is eyeing a $5 billion sale of Lyric as software dealmaking recovers from AI‑related uncertainty.
- $5 billion potential sale value
- $250 million annual EBITDA
What happened
Private‑equity firm TPG is exploring a sale of healthcare payments software company Lyric, with a potential valuation of about $5 billion.
Why it matters
The deal signals a rebound in software M&A after earlier AI‑driven sell‑offs, and highlights how specialized health‑tech firms are valued amid rapid tech change.
Short-term and longer-term
Short-term. Short‑term traders should monitor any formal announcement of the sale, the implied valuation multiples, and any ripple effects on software and healthcare indices.
Longer-term. Over the coming months, investors should assess how Lyric’s $250 million EBITDA and its role in preventing inaccurate medical claims payments position it for consolidation in the health‑tech space.